Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Sonendo, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024


Sonendo, Inc. ("Sonendo") (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Monday, March 11th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.

Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 426330. Live audio of the webcast will be available at: https://investor.sonendo.com.

An archived recording will be available on the "Investors" section of the company's website at: https://investor.sonendo.com. The webcasts will be available for replay for at least 90 days after the event.

About Sonendo

Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. Sonendo is also the parent company of TDO® Software, the developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO Software integrates practice management, imaging, referral reporting and CBCT imaging, and offers built-in communication with the GentleWave System.

For more information on Sonendo, visit www.sonendo.com. For more information on the GentleWave System, visit www.gentlewave.com/doctor.


These press releases may also interest you

at 06:05
Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer's disease (AD) and other neurodegenerative disorders, today announced the dosing...

at 06:05
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established...

at 06:05
Generate:Biomedicines Expands C-suite with Chief Corporate Affairs Officer and Chief Technical Operations Officer
Generate:Biomedicines today announces two key appointments, welcoming Kimberly (Kym) White as the new Chief Corporate Affairs Officer and announcing the promotion of Lisa Wyman to Chief Technical Operations Officer. These appointments not only...

at 06:04
Photocure ASA: Annual Report 2023
Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023. The Board of Directors of Photocure ASA has approved the annual accounts for 2023. The financial statements and annual report for the financial...

at 06:00
Avricore Health Corporate Update and Audited Results for 2023
AVRICORE HEALTH INC. (the "Company" or "AVCR") is pleased to announce its audited results for 2023. The Company nearly doubled its previous record revenues to $3,485,147 while gross profit increased by 163% to...

at 06:00
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the...

More news about Health...


News published on and distributed by: